Literature DB >> 9813068

The core binding factor (CBF) alpha interaction domain and the smooth muscle myosin heavy chain (SMMHC) segment of CBFbeta-SMMHC are both required to slow cell proliferation.

W Cao1, N Adya, M Britos-Bray, P P Liu, A D Friedman.   

Abstract

We have expressed several variants of core binding factor beta (CBFbeta)-smooth muscle myosin heavy chain (SMMHC) from the metallothionein promoter in Ba/F3 cells. Deletion of amino acids 2-11 from the CBFbeta segment, required for interaction with CBFalpha, prevented CBFbeta-SMMHC from inhibiting CBF DNA binding and cell cycle progression. Deletion of 283 carboxyl-terminal residues from the SMMHC domain, required for multimerization, also inactivated CBFbeta-SMMHC. Nuclear expression of CBFbeta(Delta2-11)-SMMHC was decreased relative to CBFbeta-SMMHC. CBFbeta(Delta2-11)-SMMHC linked to a nuclear localization signal still did not slow cell growth. The ability of each CBFbeta-SMMHC variant to inhibit CBF DNA binding and cell proliferation correlated with its ability to inhibit transactivation by an AML1-VP16 fusion protein. Thus, CBFbeta-SMMHC slows cell cycle progression from G1 to S phase by inhibiting CBF DNA binding and transactivation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9813068     DOI: 10.1074/jbc.273.47.31534

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

Review 1.  Transcriptional regulation of myelopoiesis.

Authors:  Alan D Friedman
Journal:  Int J Hematol       Date:  2002-06       Impact factor: 2.490

2.  T-cell differentiation factor CBF-β regulates HIV-1 Vif-mediated evasion of host restriction.

Authors:  Wenyan Zhang; Juan Du; Sean L Evans; Yunkai Yu; Xiao-Fang Yu
Journal:  Nature       Date:  2011-12-21       Impact factor: 49.962

3.  Multimerization via its myosin domain facilitates nuclear localization and inhibition of core binding factor (CBF) activities by the CBFbeta-smooth muscle myosin heavy chain myeloid leukemia oncoprotein.

Authors:  Tanawan Kummalue; Jianrong Lou; Alan D Friedman
Journal:  Mol Cell Biol       Date:  2002-12       Impact factor: 4.272

4.  Phosphorylation of RUNX1 by cyclin-dependent kinase reduces direct interaction with HDAC1 and HDAC3.

Authors:  Hong Guo; Alan D Friedman
Journal:  J Biol Chem       Date:  2010-11-08       Impact factor: 5.157

5.  Human CD34+ cells expressing the inv(16) fusion protein exhibit a myelomonocytic phenotype with greatly enhanced proliferative ability.

Authors:  Mark Wunderlich; Ondrej Krejci; Junping Wei; James C Mulloy
Journal:  Blood       Date:  2006-05-02       Impact factor: 22.113

Review 6.  Cell cycle and developmental control of hematopoiesis by Runx1.

Authors:  Alan D Friedman
Journal:  J Cell Physiol       Date:  2009-06       Impact factor: 6.384

7.  The core binding factor CBF negatively regulates skeletal muscle terminal differentiation.

Authors:  Ophélie Philipot; Véronique Joliot; Ouardia Ait-Mohamed; Céline Pellentz; Philippe Robin; Lauriane Fritsch; Slimane Ait-Si-Ali
Journal:  PLoS One       Date:  2010-02-25       Impact factor: 3.240

8.  Cyclin-dependent kinase phosphorylation of RUNX1/AML1 on 3 sites increases transactivation potency and stimulates cell proliferation.

Authors:  Linsheng Zhang; Florence B Fried; Hong Guo; Alan D Friedman
Journal:  Blood       Date:  2007-11-14       Impact factor: 22.113

9.  Twist-2 controls myeloid lineage development and function.

Authors:  Andrew B Sharabi; Melissa Aldrich; Drazen Sosic; Eric N Olson; Alan D Friedman; Sung-Hyung Lee; Si-Yi Chen
Journal:  PLoS Biol       Date:  2008-12-16       Impact factor: 8.029

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.